PATHOGENESIS OF PHOSPHOLIPASES A2 IN AD
AD 中磷脂酶 A2 的发病机制
基本信息
- 批准号:7192130
- 负责人:
- 金额:$ 25.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-12-01 至 2011-11-30
- 项目状态:已结题
- 来源:
- 关键词:AgeAgonistAlzheimer&aposs DiseaseAmyloidApoptoticArachidonic AcidsAstrocytesBrainCell membraneCell physiologyCellsCoculture TechniquesCollaborationsComplementary DNAConsultCytokine ActivationCytokine ReceptorsCytoplasmCytosolic Phospholipase A2DNA Sequence RearrangementDataDetectionDevelopmentDiseaseDisease ProgressionEnzymesEventGenerationsGlutamate ReceptorGlutamatesGoalsHTATIP geneHippocampus (Brain)HumanImpairmentIn VitroIndianaInflammationInflammatoryInflammatory ResponseLeadLinkLipid PeroxidationMaintenanceMediatingMembraneMembrane ProteinsMemory LossMessenger RNAMicroarray AnalysisMicrogliaMolecular Biology TechniquesMusN-MethylaspartateNADPH OxidaseNeurogliaNeuronsNitrogenNucleotidesOxidative StressOxygenP2Y2 receptorPLA2G4A genePathogenesisPathway interactionsPeptidesPharmacotherapyPhospholipase A2PhosphorylationPhosphotransferasesPlayPolymerase Chain ReactionProductionProtein KinaseProteinsRattusReceptor SignalingRegulationRelative (related person)Research PersonnelRoleSamplingSignal TransductionSliceSmall Interfering RNAStagingStatistical Data InterpretationSynaptic plasticityTestingTimeTransfectionTransgenic AnimalsTransgenic Organismsaspartate receptorbrain cellbrain tissuecognitive functioncytokinehuman PLA2G4A proteinin vivo Modelinsightlaser capture microdissectionlipid mediatormethyl(arginyl)-lysyl-prolyl-tryptophyl-tert-leucyl-leucinemigrationmouse modelmutantneuroinflammationneuron apoptosisneurotoxicnovelperoxidationprenylationprogramsprotein expressionprotein functionreceptorreceptor functionresponsetissue preparation
项目摘要
There is strong support for the hypothesis that folding of p-amyloid (AP) peptide into a neurotoxic, oligomeric
form is associated with increased oxidative stress that constitutes early events in the neuronal impairment
and glial cell-mediated inflammation seen in Alzheimer's disease (AD). Phospholipases A2 (PLA2), including
cytosolic cPLA2 and inflammatory secretory sPLA2-IIA, are important enzymes for the production of lipid
mediators and the maintenance of membrane integrity. Although these enzymes have been implicated in
other diseases, their roles in the pathogenesis of AD have not been explored sufficiently. Our recent studies
have obtained novel data indicating that oligomeric Ap42 treatment of neurons enhances ROS production
through NADPH oxidase and increases cPLA2 activity through intracellular kinase activation, resulting in
membrane peroxidation and alterations in membrane protein function. Other new data show that sPLA2-IIA
mRNA and protein expression are elevated in AD brain compared to age-matched controls. The overall
goal of this project is to understand mechanisms whereby A|3, NADPH oxidase, cPLA2 and sPLA2-IIA
collectively contribute to impairment of neuronal function and induction of glial-cell mediated
inflammation, using accepted and novel in vitro and in vivo models of AD.Aim 1tests the hypothesis
that Ap-induced cPLA2 and NADPH oxidase activation in neurons serves to modulate N-methyl-D-aspartic
acid (NMDA) receptor function and induce neuronal apoptosis. Aim 2 investigates the significance and
relevance to AD pathogenesis of the novel preliminary data indicating that sPLA2-IIA is up-regulated in AD
and tests the hypothesis that increases in sPLA2-IIA expression caused by oligomeric Ap42 and NADPH
oxidase-dependent ROS generation modulate inflammatory responses in glial cells and cause neuronal
apoptosis. We will test the hypothesis that NADPH oxidase and cPLA2 up-regulate sPLA2-IIA expression
and modulate inflammatory responses in glial cells, thus linking oxidative pathways to neuroinflammation.
Proposed studies to evaluate novel roles for PLA2s in neuronal and glial cell functions associated with AD
will evaluate responses in primary neurons and astrocytesfrom the TgCRNDS mouse model of AD, NT-2
cells over-expressing the Swedish/Indiana mutant of APP, human AD and non-demented (ND) brain tissue,
and brain slices from transgenic mouse models, including TgCRNDS and TgCRNDS x sPLA2-IIA, and mice
lacking cPLA2 and gp91phox, a NADPH oxidase subunit. Together, these studies will provide new
information about the roles of neuronal cPLA2 in enhancing oxidative stress and impairing glutamatergic
signaling in the early stages of AD, and the role of sPLA2-IIA in inflammatory responses in glial cells,
information that we believe can lead to novel pharmacotherapies to retard disease progression.
对p-淀粉样蛋白(AP)肽折叠成神经毒性低聚物的假设有强有力的支持
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GRACE Y SUN其他文献
GRACE Y SUN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GRACE Y SUN', 18)}}的其他基金
Satellite Symposium on "Novel Strategies for Intervention in Neurodegenerative Di
“神经退行性疾病干预新策略”卫星研讨会
- 批准号:
7749492 - 财政年份:2009
- 资助金额:
$ 25.75万 - 项目类别:
Conference on Oxidative Mechanisms in Neurodegeneration
神经变性氧化机制会议
- 批准号:
6710407 - 财政年份:2004
- 资助金额:
$ 25.75万 - 项目类别:
Cell Models for AD: Lipids and Related Signaling Pathways
AD 细胞模型:脂质和相关信号通路
- 批准号:
7410043 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
Cell Models for AD: Lipids and Related Signaling Pathways
AD 细胞模型:脂质和相关信号通路
- 批准号:
7618395 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
Cell Models for Alzheimer's disease (AD): Lipids and Related Signaling Pathways
阿尔茨海默病 (AD) 细胞模型:脂质和相关信号通路
- 批准号:
8530657 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
Cell Models for AD: Lipids and Related Signaling Pathways
AD 细胞模型:脂质和相关信号通路
- 批准号:
7822734 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
Cell models for AD:Lipids and related signaling pathways
AD 细胞模型:脂质和相关信号通路
- 批准号:
6733559 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
Cell models for AD:Lipids and related signaling pathways
AD 细胞模型:脂质和相关信号通路
- 批准号:
6509922 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
Cell models for AD:Lipids and related signaling pathways
AD 细胞模型:脂质和相关信号通路
- 批准号:
6882626 - 财政年份:2001
- 资助金额:
$ 25.75万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 25.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 25.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 25.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)